硬纤维瘤治疗策略的变化及新进展  

Changes and development in the management of desmoid tumors

作　　者：李舒(综述)[1] 方志伟(审校)[1] Shu Li;Zhiwei Fang(Department of Bone and Soft Tissue Tumors,Peking University Cancer Hospital&Institute,Key laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Beijing 100142,China)

机构地区：[1]北京大学肿瘤医院暨北京市肿瘤防治研究所骨与软组织肿瘤科,恶性肿瘤发病机制及转化研究教育部重点实验室,北京市100142

出　　处：《中国肿瘤临床》2023年第3期130-134,共5页Chinese Journal of Clinical Oncology

基　　金：吴阶平医学基金会临床科研专项资助基金(编号:320.6750.18471);希思科-石药肿瘤研究基金项目(编号:Y-sy2018-152)资助。

摘　　要：硬纤维瘤是一种罕见的中间性肿瘤,可侵袭性生长、罕见恶变、不会转移。对于该病,传统的治疗理念是手术切除。但近年来,该病的治疗理念发生了巨大变化,治疗策略越来越趋向于保守,不仅体现在药物治疗地位的提高,手术、放疗地位的下降,更体现在密切监测作为一线治疗策略取代了以往确诊即治疗的理念。新的药物及新的治疗方法逐渐涌现,为硬纤维瘤患者提供了更多的治疗选择。Desmoid tumors(DTs)are rare intermediately malignant locally aggressive tumors that seldom cancerate and never metastasize.DTs are traditionally managed via radical resection.Throughout the years,disease management has evolved to utilize more conservative treatment strategies.This shift in treatment strategy does not only reflect the increased use of systemic treatment and the decreased use of resection and radiotherapy but also highlights the effectiveness of active surveillance as a first-line treatment strategy,replacing the previous concept of“diagnosis-then-treatment.”Novel drugs and treatment strategies are emerging,providing more treatment options for patients with DTs.

关 键 词：硬纤维瘤 药物治疗 治疗策略 

分 类 号：R730.5[医药卫生—肿瘤]